Aminoguanidine prolongs survival in azotemic-induced diabetic rats

American Journal of Kidney Diseases

Volumn 30, Issue 2, 1997, Pages 253-259

  Friedman, Eli A ^a   Distant, Dale A ^b   Fleishhacker, Jordan F ^b   Boyd, Thomas A ^b   Cartwright, Kenneth ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NONE

Author keywords

Aminoguanidine; Diabetes; Nephropathy; Rats; Survival

Indexed keywords

AMINOGUANIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; GLOMERULUS FILTRATION; GLYCOSYLATION; HYPERGLYCEMIA; KIDNEY FUNCTION; NONHUMAN; RAT; STREPTOZOCIN DIABETES; SURVIVAL; UREMIA;

EID: 0030838989     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90060-3     Document Type: Article

References (46)

1. U.S. Renal Data System, USRDS 1996 Annual Data Report, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, April 1996
2. Porte D Jr, Schwartz MW: Diabetes complications: Why is glucose potentially toxic? Science 272:699-670, 1996
3. Derubertis FR, Craven PA: Activation of protein kinase C in glomerular cells in diabetes: Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 431-438, 1994
4. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell S-E, Kern TS, Ballas LM, Heath WF, Stamm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC 13 inhibitor. Science 272:728-731, 1996
5. Yamaoka T, Nishimura C, Yamashita K, Itakura M, Yamada T, Fujimoto J, Kokai Y: Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia 38:255-261, 1995
6. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
7. Vlassara H, Bucala R, Striker L: Pathogenic effects of advanced glycosylation: Biochemical, biological, and clinical implications for diabetes and aging. J Lab Invest 70:138-151, 1994
8. Sell DR, Monnier VM: End stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. J Clin Invest 85:380-384, 1990
9. Bucala R, Vlassara H: Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 6:875-888, 1995
10. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM- 1) in cultured human endothelial cells and in mice. J Clin Invest 96:1395-1403, 1995
11. Wautier J-L, Zooukourian C, Chappey O, Wautier M-P, Guillausseau P-J, Rong C, Osamu H, Stern D, Schmidt AM: Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 97:238-243, 1996
12. Edelstein D, Brownlee M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 41:26-29, 1992
13. Swamy-Mruthinti S, Green K, Abraham EC: Inhibition of cataracts in moderately diabetic rats by amonguanidine. Exp Eye Res 62:505-510, 1996
14. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diaabetic nephropathy in the Sprague-Dawley rat. Diabetologia 38:387-394, 1995
15. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K: Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 37:32-35, 1994
16. Miyauchi Y, Shikama H, Takasu T, Okamiya H, Umeda M, Hirasaki E, Ohhata I, Nakayama H, Hakagawa S: Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in strptozotocin-induced diabetic rats. Eur J Endocrinol 134:467-473, 1996
17. Norton GR, Candy G, Woodiwiss AJ: Aminoguanidine prevents the decreased myocardial compliance produced by strptozotocin-induced diabetes mellitus in rats. Circulation 93:1905-1912, 1996
18. Archibald V, Cotter MA, Keegan A, Cameron NE: Contraction and relaxation of aortas from diabetic rats: Effects of chronic anti-oxidant and aminoguanidine treatments. Naunyn-Schmiedbergs Arch Pharm 353:584-591, 1996
19. Brownlee M: Pharmacological modulation of the advanced glycosylation reaction. Prog Clin Biol Res 304:235-248, 1989
20. Nicholls K, Mandel TE: Advanced glycosylation end-products in experimental murine diabetic nephropathy: Effect of islet isografting and of aminoguanidine. Lab Invest 60:486-491, 1989
21. Lyons TJ, Dailie KE, Dyer DG, Dunn JA, Baynes JW: Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J Clin Invest 87:1910-1915, 1991
22. Makita Z, Vlassara H, Cerami A, Bucala R: Immuno-logical detection of advanced glycosylated end products in vivo. Biol Chem 267:5133-5138, 1992
23. Sabbatini M, Sansone G, Uccello F, Giliberti A, Conte G, Andreucci VE: Early glycosylation products induce glomerular hyperfiltration in normal rats. Kidney Int 42:875-881, 1992
24. Wald H, Markowitz H, Zevin S, Popovtzer MM: Opposite effects of diabetes on nephrotoxic and ischemic acute tubular necrosis. Proc Soc Exp Biol Med 195:51-56, 1990
25. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes 40:1328-1334, 1991
26. Makino H, Yamasaki Y, Hironaka K, Ota Z: Glomerular extracellular matrices in rat diabetic glomerulopathy by scanning electron microscopy. Virchows Arch B Cell Pathol 62:19-24, 1992
27. Petersen J, Ross J, RabLin R: Effect of insulin therapy on established diabetic nephropathy in rats. Diabetes 37:1346-1350, 1988
28. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91:11704-11708, 1994
29. Vlassara H: Serum advanced glycosylation end products: A new class of uremic toxins? Blood Purif 12:54-59, 1994
30. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP: Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 46:216-222, 1994
31. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325:836-842, 1991
32. Moncado S, Palmer RMJ, Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109-142, 1991
33. Bank N, Aynedjian HS: Tole of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 43:1306-1312, 1993
34. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 87:432-438, 1991
35. Stevens MJ, Dananberg J, Feldman EL, Lattimer SA, Kamijo M, Thomas TP, Shindo H, Sima AF, Greene DA: The linked roles of nitric oxide, aldose reductase, and, Na+, K+) ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 94:853-859, 1994
36. Thorup C, Erik A, Persson G: Macula densa derived nitric oxide in regulation of glomerular capillary pressure. Kidney Int 49:430-436, 1996
37. Cameron NE, Cotter MA: Rapid reversal by amino-guanidine of the neruorvascular effects of diabetes in rats: Modulation by nitric oxide synthase inhibition. Metabolism 45:1147-1152, 1996
38. Scott JA, Machoun M, McCormack DG: Inducible nitric oxide synthase and vascular reactivity in rat thoracic aorta: Effect of aminoguanidine. J Appl Physiol 80:271-277, 1996
39. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M: Aminoguanidine treatment inhibits the develop-ment of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 88:11555-11558, 1991
40. Yagihashi S, Kamijo M, Baba M, Yagihashi M, Nagai K: Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 41:47-52, 1992
41. Paul RG, Bailey AJ: Glycation of collagen: the basis of its central role in the late complications of aging and diabetes. Int J Biochem Cell Biol 28:1297-1310, 1996
42. Tajiri Y, Moller C, Grill V: Long term effects of aminoguanidine on insulin relase and biosynthesis: Evidence that the formation of advanced glycosylated end products inhibits B cell function. Endocrinology 138:17-24, 1997
43. Valesquez MT, Kimmel PL, Michaelis OE IV: Animal models of spontaneous diabetic kidney disease. FASEB J 4:2850-2859, 1990
44. Vora JP, Zimsen SM, Houghton DC, Anderson S: Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes. J Am Soc Nephrol 7:113-117, 1996
45. Brownlee M: Glycation and diabetic complications. Diabetes 48:837-841, 1994
46. Friedlander MA, Wu YC, James MS, Schulak A, Monnier VM, Hrickik DE: Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end stage renal disease. Am J Kidney Dis 25:445-451, 1995